Glenmark Pharmaceuticals reported strong Q3 FY26 results with consolidated revenue at Rs. 39,006 Mn, a 15.1% YoY increase. India formulations revenue grew by 22.1% to Rs. 12,986 Mn. EBITDA stood at Rs. 8,697 Mn, up 44.9% YoY, with a margin of 22.3%. Profit After Tax (PAT) was Rs. 4,032 Mn, a 15.9% YoY rise, with a 10.3% margin.
Financial Highlights for Q3 FY26
Glenmark Pharmaceuticals announced its financial results for the third quarter ending December 31, 2025, showcasing significant growth across various segments:
- India Formulations: Revenue increased by 22.1% YoY, reaching Rs. 12,986 Mn.
- North America: Revenue grew by 24.2% YoY to Rs. 9,706 Mn, including out-licensing income.
- Europe: Revenue rose by 9.1% YoY to Rs. 7,963 Mn.
- Emerging Markets: Revenue increased by 8.4% YoY to Rs. 8,119 Mn.
- EBITDA: Achieved Rs. 8,697 Mn, a 44.9% YoY increase, with an EBITDA margin of 22.3%.
- Profit After Tax (PAT): Reached Rs. 4,032 Mn, a 15.9% YoY increase, with a PAT margin of 10.3%.
Revenue Performance
Consolidated revenue for Q3 FY26 reached Rs. 39,006 Mn, compared to Rs. 33,876 Mn in the corresponding quarter of the previous year, marking a 15.1% YoY growth. For the nine months of FY26, Glenmark’s consolidated revenue was Rs. 132,119 Mn, compared to Rs. 1,00,655 Mn in the previous year, reflecting a 31.3% YoY growth.
Key Strategic Developments
Glenmark has focused on key strategic developments during the quarter, including:
- Launch of NEBZMART® GFB Smartules® and Glenmark AIRZ® FB Smartules®, the world’s first nebulized, fixed-dose triple therapy for COPD.
- Partnership with BeOne Medicines for TEVIMBRA® (Tislelizumab) & BRUKINSA® (Zanubrutinib).
- The company was the first to launch the biosimilar of Liraglutide under the brand name LIRAFIT™ in India.
North America Outlook
North America recorded revenues of Rs. 9,706 Mn for Q3 FY26. The company launched 4 products, and plans to file three ANDAs in the upcoming quarter. Glenmark received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Monroe.
Global Innovative Portfolio
- RYALTRIS® marketing applications have been submitted to over 90 countries and is commercialized in 52 markets.
- WINLEVI® launched in the UK and saw strong uptake.
- Glenmark filed QiNHAYO™ MA Applications in 18 markets.
- Advancements for initiation of MA applications for Trastuzumab Rezetecan.
- Glenmark entered into an agreement for Aumolertinib.
Source: BSE
